WHO ICTRP trial
Efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients…
EUCTR2020-001413-20-ES · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2020-001413-20-ES |
|---|---|
| Public title | Efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID-19 pneumonia |
| Scientific title | Phase 2, randomized, open-label study to compare the efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID19 pneumonia |
| Primary sponsor | Fundació Clínic per a la Recerca Biomèdica |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Spain |
| Conditions | COVID19;Therapeutic area: Diseases [C] - Virus Diseases [C02] |
| Interventions | Trade Name: Sylvant Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Siltuximab CAS Number: 541502-14-1 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration… |
| Registration date | Apr 13, 2020 |
| Target size | 100 |
| Secondary IDs | SILCOR-COVID19 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: